Cerebral Palsy has been linked to a condition called cryptorchidism in males - when one or both of the testicles are not present in the scrotum. A new study in Developmental Medicine & Child Neurology ...
The FDA has approved the expanded use of Botox® (onabotulinumtoxinA; Allergan) for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by ...
Botulinum toxin is an established antispastic treatment for children with cerebral palsy (CP), but its effect on adductor spasticity—an important risk factor for hip dislocation—has not been ...
Purpose To develop a patient-reported outcome measure for spasticity-related pain in children/adolescents (age 2–17 years) with cerebral palsy (CP), the 'Questionnaire on Pain caused by Spasticity ...
The Food and Drug Administration has approved expanded use of Dysport to treat upper- and lower-limb spasticity – including that caused by cerebral palsy – for patients as young as 2 years and older, ...
NORTH CHICAGO, Ill., July 9, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License ...
"Spasticity Pipeline Insight"The spasticity treatment pipeline is rapidly evolving to meet the need for safer, longer-lasting, and more targeted therapies. Common in conditions like cerebral palsy, MS ...
Cerebral palsy, a non-progressing motor impairment that begins in early childhood, has widely been viewed as the result of oxygen deprivation during birth or other birth-related factors such as ...
DUBLIN, Oct. 24, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback